<DOC>
	<DOC>NCT00232050</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of omalizumab up to 16 weeks in adult patients with moderate to severe bronchial asthma.</brief_summary>
	<brief_title>Study of Omalizumab in Moderate to Severe Bronchial Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Allergic asthma patients Inadequately controlled patients History of severe anaphylactoid or anaphylactic reactions Previous treatment with omalizumab History of cancer or cancer Other protocoldefined exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Asthma, IgE, Omalizumab</keyword>
</DOC>